Drug Profile
Calcitonin gene-related peptide gene therapy
Latest Information Update: 01 May 2002
Price :
$50
*
At a glance
- Originator Nonindustrial source
- Class Gene therapies; Neuropeptides
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cerebrovascular disorders
Most Recent Events
- 31 Oct 2000 New profile
- 31 Oct 2000 Preclinical development for Cerebrovascular disorders in USA (Unknown route)